Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the initiation of patient screening in a Phase 1 clinical trial of APD916, a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE